X4 Pharmaceuticals, Inc. Common Stock (XFOR) Stock Price

XFORStock

$4.04−1.94%52W

Market Cap$400.55M

P/E—

PEG Ratio—

Div yield—

Beta0.42

XFOR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)7.24%

Price vs S&P 500 (4W)-2.76%

VGM Score43.51

Book Value / Share (Quarterly)$1.79

P/TBV (Annual)2.06x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-5.19%

Cash Flow / Share (Quarterly)$-0.98

Price vs S&P 500 (YTD)-11.82%

Gross Margin (TTM)81.82%

Net Profit Margin (TTM)-1106.30%

EPS (TTM)$-4.58

10-Day Avg Trading Volume0.60M

EPS Excl Extra (TTM)$-4.58

Revenue Growth (5Y)58.59%

EPS (Annual)$-1.87

ROI (Annual)-30.16%

Gross Margin (Annual)83.60%

Net Profit Margin (5Y Avg)-5238.80%

Cash / Share (Quarterly)$2.48

Revenue Growth QoQ (YoY)-90.60%

ROA (Last FY)-27.27%

Revenue Growth TTM (YoY)-71.26%

EBITD / Share (TTM)$-1.44

ROE (5Y Avg)-134.80%

Operating Margin (TTM)-1084.38%

Cash Flow / Share (Annual)$-0.97

P/B Ratio2.40x

P/B Ratio (Quarterly)2.23x

Net Income / Employee (Annual)$-1,760,000

EV / Revenue (TTM)29.31x

Net Interest Coverage (TTM)-17.41x

ROA (TTM)-48.09%

EV / EBITDA (TTM)11.67x

EPS Incl Extra (Annual)$-1.87

Current Ratio (Annual)10.16x

Quick Ratio (Quarterly)9.90x

3-Month Avg Trading Volume0.65M

52-Week Price Return-1.94%

Revenue / Employee (TTM)$200,300

Tangible BV / Share (Quarterly)$1.69

P/S Ratio (Annual)11.52x

Asset Turnover (Annual)0.12x

52-Week High$4.83

Operating Margin (5Y Avg)-5090.25%

EPS Excl Extra (Annual)$-1.87

CapEx CAGR (5Y)17.14%

Tangible BV CAGR (5Y)-0.69%

26-Week Price Return19.17%

Quick Ratio (Annual)9.88x

13-Week Price Return-2.42%

Total Debt / Equity (Annual)0.41x

Current Ratio (Quarterly)10.18x

Enterprise Value$264.24M

Revenue / Share Growth (5Y)-10.81%

Asset Turnover (TTM)0.04x

Book Value / Share Growth (5Y)-14.43%

Revenue / Employee (Annual)$780,300

Pretax Margin (Annual)-225.44%

Cash / Share (Annual)$2.78

3-Month Return Std Dev65.34%

Net Income / Employee (TTM)$-2,216,000

ROE (Last FY)-42.51%

Net Interest Coverage (Annual)-30.63x

EPS Basic Excl Extra (Annual)$-1.87

Receivables Turnover (TTM)11.11x

Total Debt / Equity (Quarterly)0.45x

EPS Incl Extra (TTM)$-4.58

ROI (TTM)-55.02%

P/S Ratio (TTM)44.89x

Pretax Margin (5Y Avg)-5235.83%

Revenue / Share (Annual)$0.83

Tangible BV / Share (Annual)$1.95

Price vs S&P 500 (52W)-20.50%

Year-to-Date Return1.00%

5-Day Price Return-0.25%

EPS Normalized (Annual)$-1.87

ROA (5Y Avg)-51.51%

Net Profit Margin (Annual)-225.55%

Month-to-Date Return1.51%

Cash Flow / Share (TTM)$-0.72

EBITD / Share (Annual)$-2.02

Operating Margin (Annual)-247.44%

LT Debt / Equity (Annual)0.41x

ROI (5Y Avg)-68.33%

LT Debt / Equity (Quarterly)0.45x

EPS Basic Excl Extra (TTM)$-4.58

P/TBV (Quarterly)2.36x

P/B Ratio (Annual)1.96x

Inventory Turnover (TTM)0.42x

Pretax Margin (TTM)-1106.22%

Book Value / Share (Annual)$2.05

Price vs S&P 500 (13W)-4.37%

Beta0.42x

Revenue / Share (TTM)$0.07

ROE (TTM)-94.90%

52-Week Low$2.80

vGradeC

gGradeD

mGradeC

vgmGradeC

XFOR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.18	-$0.13	+27.78%(+$0.05)
Q1 2026	May 6, 2026	-$0.20	-$0.16	+20.00%(+$0.04)
Q4 2025	Mar 17, 2026	-$0.35	-$0.22	+36.69%(+$0.13)
Q3 2025	Nov 5, 2025	-$0.84	-$0.69	+18.18%(+$0.15)
Q2 2025	Aug 8, 2025	-$4.34	-$3.47	+19.98%(+$0.87)

XFOR Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.33

4.40

4.36

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
XFORX4 Pharmaceuticals, Inc. Common Stock	C	D	C	$4.04
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About X4 Pharmaceuticals, Inc. Common Stock

X4 Pharmaceuticals develops therapies for rare immune system disorders. Its lead candidate mavorixafor is an oral, once-daily CXCR4 antagonist designed to increase white blood cell mobilization from the bone marrow. The company has two additional CXCR4-based candidates in preclinical development.